湖州市艾滋病患者HAART治疗后生存状况的影响因素

IF 2.6 4区 医学 Q3 INFECTIOUS DISEASES
Meihua Jin, Zhongrong Yang, Jing Li, Xiaoqi Liu, Zhenqian Wu
{"title":"湖州市艾滋病患者HAART治疗后生存状况的影响因素","authors":"Meihua Jin,&nbsp;Zhongrong Yang,&nbsp;Jing Li,&nbsp;Xiaoqi Liu,&nbsp;Zhenqian Wu","doi":"10.1155/2022/2787731","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Highly active antiretroviral therapy (HAART) can effectively reduce the risk of death and opportunistic infections in patients with HIV/AIDS. The aim of this study was to analyse the survival status and its influencing factors in HIV/AIDS after HAART.</p><p><strong>Methods: </strong>The data on patients' sociodemographic characteristics, treatment information, and follow-up results from the Information Management System of the Chinese Center for Disease Control and Prevention were obtained. Bivariate and stepwise multivariate Cox proportional hazards regression model analyses were performed.</p><p><strong>Results: </strong>A total of 1812 participants were included in this study, of which 1716 were still alive (survival group) and 96 had died (death group). The results indicated that respondents who were elderly (<i>HR</i> = 1.053, 95% <i>CI</i>: 1.037-1.069, <i>P</i> < 0.01), who had heterosexual transmission (<i>HR</i> = 2.422, 95% <i>CI</i>: 1.314-4.465, <i>P</i> < 0.01) and whose current WHO clinical stage was stage III or IV (<i>HR</i> = 2.399, 95% <i>CI</i>: 1.215-4.735, <i>P</i> < 0.05) were more likely to have died; respondents whose baseline CD4<sup>+</sup> T-lymphocyte count was equal to or more than 200 cells/<i>μ</i>L (<i>HR</i> = 0.412, 95% <i>CI</i>: 0.275-0.616, <i>P</i> < 0.05) were unlikely to have died.</p><p><strong>Conclusions: </strong>It is recommended that HAART be provided to HIV/AIDS patients at an early clinical stage and that the health services for HIV/AIDS patients after taking medicines be strengthened, which will help promote adherence to therapeutic regimens and improve quality of life.</p>","PeriodicalId":50715,"journal":{"name":"Canadian Journal of Infectious Diseases & Medical Microbiology","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560853/pdf/","citationCount":"5","resultStr":"{\"title\":\"Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.\",\"authors\":\"Meihua Jin,&nbsp;Zhongrong Yang,&nbsp;Jing Li,&nbsp;Xiaoqi Liu,&nbsp;Zhenqian Wu\",\"doi\":\"10.1155/2022/2787731\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Highly active antiretroviral therapy (HAART) can effectively reduce the risk of death and opportunistic infections in patients with HIV/AIDS. The aim of this study was to analyse the survival status and its influencing factors in HIV/AIDS after HAART.</p><p><strong>Methods: </strong>The data on patients' sociodemographic characteristics, treatment information, and follow-up results from the Information Management System of the Chinese Center for Disease Control and Prevention were obtained. Bivariate and stepwise multivariate Cox proportional hazards regression model analyses were performed.</p><p><strong>Results: </strong>A total of 1812 participants were included in this study, of which 1716 were still alive (survival group) and 96 had died (death group). The results indicated that respondents who were elderly (<i>HR</i> = 1.053, 95% <i>CI</i>: 1.037-1.069, <i>P</i> < 0.01), who had heterosexual transmission (<i>HR</i> = 2.422, 95% <i>CI</i>: 1.314-4.465, <i>P</i> < 0.01) and whose current WHO clinical stage was stage III or IV (<i>HR</i> = 2.399, 95% <i>CI</i>: 1.215-4.735, <i>P</i> < 0.05) were more likely to have died; respondents whose baseline CD4<sup>+</sup> T-lymphocyte count was equal to or more than 200 cells/<i>μ</i>L (<i>HR</i> = 0.412, 95% <i>CI</i>: 0.275-0.616, <i>P</i> < 0.05) were unlikely to have died.</p><p><strong>Conclusions: </strong>It is recommended that HAART be provided to HIV/AIDS patients at an early clinical stage and that the health services for HIV/AIDS patients after taking medicines be strengthened, which will help promote adherence to therapeutic regimens and improve quality of life.</p>\",\"PeriodicalId\":50715,\"journal\":{\"name\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2022-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560853/pdf/\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Infectious Diseases & Medical Microbiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2022/2787731\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Infectious Diseases & Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2022/2787731","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 5

摘要

背景:高效抗逆转录病毒治疗(HAART)可有效降低HIV/AIDS患者的死亡和机会性感染风险。本研究的目的是分析HAART治疗后HIV/AIDS患者的生存状况及其影响因素。方法:从中国疾病预防控制中心信息管理系统获取患者的社会人口学特征、治疗信息及随访结果。进行双变量和逐步多变量Cox比例风险回归模型分析。结果:本研究共纳入1812例受试者,其中1716例仍健在(生存组),96例已死亡(死亡组)。结果显示,老年人(HR = 1.053, 95% CI: 1.037 ~ 1.069, P < 0.01)、异性传播者(HR = 2.422, 95% CI: 1.314 ~ 4.465, P < 0.01)、who临床分期为III期或IV期者(HR = 2.399, 95% CI: 1.215 ~ 4.735, P < 0.05)的死亡风险较高;基线CD4+ t淋巴细胞计数≥200个/μL (HR = 0.412, 95% CI: 0.275 ~ 0.616, P < 0.05)的应答者不太可能死亡。结论:建议在临床早期阶段为艾滋病患者提供HAART治疗,并加强对服药后艾滋病患者的卫生服务,有助于提高患者对治疗方案的依从性,提高患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.

Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.

Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.

Factors Influencing Survival Status of HIV/AIDS after HAART in Huzhou City, Eastern China.

Background: Highly active antiretroviral therapy (HAART) can effectively reduce the risk of death and opportunistic infections in patients with HIV/AIDS. The aim of this study was to analyse the survival status and its influencing factors in HIV/AIDS after HAART.

Methods: The data on patients' sociodemographic characteristics, treatment information, and follow-up results from the Information Management System of the Chinese Center for Disease Control and Prevention were obtained. Bivariate and stepwise multivariate Cox proportional hazards regression model analyses were performed.

Results: A total of 1812 participants were included in this study, of which 1716 were still alive (survival group) and 96 had died (death group). The results indicated that respondents who were elderly (HR = 1.053, 95% CI: 1.037-1.069, P < 0.01), who had heterosexual transmission (HR = 2.422, 95% CI: 1.314-4.465, P < 0.01) and whose current WHO clinical stage was stage III or IV (HR = 2.399, 95% CI: 1.215-4.735, P < 0.05) were more likely to have died; respondents whose baseline CD4+ T-lymphocyte count was equal to or more than 200 cells/μL (HR = 0.412, 95% CI: 0.275-0.616, P < 0.05) were unlikely to have died.

Conclusions: It is recommended that HAART be provided to HIV/AIDS patients at an early clinical stage and that the health services for HIV/AIDS patients after taking medicines be strengthened, which will help promote adherence to therapeutic regimens and improve quality of life.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
108
审稿时长
>12 weeks
期刊介绍: Canadian Journal of Infectious Diseases and Medical Microbiology is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to infectious diseases of bacterial, viral and parasitic origin. The journal welcomes articles describing research on pathogenesis, epidemiology of infection, diagnosis and treatment, antibiotics and resistance, and immunology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信